Paul G. Auwaerter, M.D., Kathryn Dzintars, Pharm.D., BCPS
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS



  • Remdesivir is approved for the treatment of coronavirus disease 2019 (COVID-19) in adult and pediatric patients (28 days of age and older and who weigh at least 3 kg) who:
    • Require hospitalization
    • Have positive results of direct SARS-CoV-2 viral testing, who are not hospitalized, have mild to moderate symptoms, and are at high risk for progression to severe COVID-19, including hospitalization or death
  • Severe disease is defined as:
    • Patients with SpO2 ≤ 94% on room air, OR
    • Requiring supplemental oxygen, OR
    • Requiring mechanical ventilation, OR
    • Requiring extracorporeal membrane oxygenation (ECMO)


  • Nonhospitalized patients at high risk for disease progression may be given a 3-day course of remdesivir (200 mg IV on day 1, then 100 mg IV on days 2 and 3).

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: August 3, 2023